Raleigh Urologist, Dr. John Kaspar, Named UroLift® Center of Excellence

Share Article

Designation Recognizes Practice’s Commitment to Exemplary Care, Deep UroLift Experience

I am proud to be a national leader offering this breakthrough procedure called UroLift.

Associated Urologists of North Carolina, PA today announced that Dr. John Kaspar, M.D. has been named a UroLift® Center of Excellence. This recognition is based on his commitment to exemplary care for men suffering from urinary tract symptoms and his high level of training and experience with the UroLift System in treating men with Benign Prostatic Hyperplasia or BPH. Dr. Kaspar is the first UroLift Center of Excellence in the state of North Carolina and the eleventh physician to receive this distinction nationwide.

Dr. Kaspar frequently hears the same scenarios from men over age 50; “I’m tired, I’ve got to change my clothes with all the dribbling of urine after I urinate; it’s embarrassing.” And “I want to sit and watch a ballgame, but I end up spending more time in the bathroom.”

“What these men are describing are the infuriating signs and symptoms of an enlarged prostate, or what is commonly called BPH,” says Dr. Kaspar. “This enlarged prostate is actually blocking the urine tube that passes through the prostate that is supposed to effectively empty the bladder.” Symptoms of BPH can significantly impact a patient’s quality of life due to interrupted sleep and loss of productivity. Dr. Kaspar continues, “I am proud to be a national leader offering this breakthrough procedure called UroLift.”

The UroLift System is a proven treatment that can get men off BPH medications and allow them to avoid major surgery, while preserving sexual function. Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

More than 37 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

To schedule a consultation with Dr. Kaspar, please call 919-390-7373.

About the UroLift System

NeoTract Inc.’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at http://www.UroLift.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sierra Smith
+1 4085404296
Email >